Wave Life Sciences (WVE) Stock Forecast & Price Target

Compare

1,127 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

WVE Analyst Ratings

Strong Buy

14 Buy

0 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Wave

Life Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

WVE Stock 12 Month Forecast

Average Price Target

$33.00

▲(117.82% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Wave Life Sciences in the last 3 months. The average price target is $33.00 with a high forecast of $50.00 and a low forecast of $21.00. The average price target represents a 117.82% change from the last price of $15.15.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"5":"$5","28":"$28","51":"$51","16.5":"$16.5","39.5":"$39.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":50,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$50.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$33.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$21.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[5,16.5,28,39.5,51],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17,19.53846153846154,22.076923076923077,24.615384615384613,27.153846153846153,29.692307692307693,32.230769230769226,34.76923076923077,37.30769230769231,39.84615384615385,42.38461538461539,44.92307692307692,47.46153846153846,{"y":50,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17,18.23076923076923,19.46153846153846,20.692307692307693,21.923076923076923,23.153846153846153,24.384615384615387,25.615384615384617,26.846153846153847,28.076923076923077,29.307692307692307,30.53846153846154,31.76923076923077,{"y":33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17,17.307692307692307,17.615384615384617,17.923076923076923,18.23076923076923,18.53846153846154,18.846153846153847,19.153846153846153,19.46153846153846,19.76923076923077,20.076923076923077,20.384615384615387,20.692307692307693,{"y":21,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.37,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.57,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.74,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.94,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.25,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.52,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.63,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.62,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.41,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$50.00

Average Price Target$33.00

Lowest Price Target$21.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Andrew Fein

H.C. Wainwright

$30

Buy

98.02%

Upside

Reiterated

01/07/26

Valuation and Risks. Our price target of $30 is based on an equally weighted composite of: (a) $30/share, as a 25x multiple of taxed and diluted FY34 GAAP EPS of $3 discounted back to and (b) an NPV of $29/share (discount rate 11%, growth rate 3%). Risks to our investment thesis and price target include: (1) failure of in clinical studies; (2) failure of to secure regulatory approval; and (3) failure of to achieve peak commercial revenue estimates in our model due to market size, penetration size, and/or pricing.

William Maughan

Clear Street

$22→$47

Buy

210.23%

Upside

Reiterated

01/06/26

Wave Life Sciences (WVE) Gets a Buy from Clear Street

Yun Zhong

Wedbush

$33

Buy

117.82%

Upside

Reiterated

01/06/26

Wave Life Sciences: Validated INHBE Mechanism, Promising WVE-007 Clinical Path, and GLP-1 Combination Upside Support Buy Rating

Benjamin Burnett

Wells Fargo

$29

Buy

91.42%

Upside

Reiterated

12/17/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioCryst (NASDAQ: BCRX), Wave Life Sciences (NASDAQ: WVE) and Alkermes (NASDAQ: ALKS)

Cheng Li

Oppenheimer

$24→$32

Buy

111.22%

Upside

Reiterated

12/16/25

Wave Life Sciences price target raised to $32 from $24 at OppenheimerWave Life Sciences price target raised to $32 from $24 at Oppenheimer

Joon Lee

Truist Financial

$36→$50

Buy

230.03%

Upside

Reiterated

12/15/25

Wave Life Sciences (WVE) Receives a Rating Update from a Top Analyst

Madison Elsaadi

B. Riley Securities

$19→$37

Buy

144.22%

Upside

Reiterated

12/11/25

Wave Life Sciences (WVE) Receives a Buy from B. Riley Securities

Steven Seedhouse

Cantor Fitzgerald

$12→$34

Buy

124.42%

Upside

Reiterated

12/09/25

Wave Life Sciences price target raised to $34 from $12 at Cantor FitzgeraldWave Life Sciences price target raised to $34 from $12 at Cantor Fitzgerald

Samantha Semenkow

Citi

$16→$30

Buy

98.02%

Upside

Reiterated

12/09/25

Wave Life Sciences price target raised to $30 from $16 at CitiWave Life Sciences price target raised to $30 from $16 at Citi

Joseph Schwartz

Leerink Partners

$240→$26

Buy

71.62%

Upside

Reiterated

12/08/25

Promising Potential of Wave Life Sciences' WVE-007: A Competitive Candidate in the Weight Loss Market

Whitney Ijem

Canaccord Genuity

$19→$40

Buy

164.03%

Upside

Reiterated

12/08/25

Wave Life Sciences price target raised to $40 from $19 at CanaccordWave Life Sciences price target raised to $40 from $19 at Canaccord

Martin Auster

Raymond James

$21

Buy

38.61%

Upside

Reiterated

12/08/25

Wave Life Sciences' WVE-007: Promising Data and Safety Profile Elevate Buy Rating and Price Target

Luca Issi

RBC Capital

$9→$27

Buy

78.22%

Upside

Upgraded

12/08/25

Wave Life Sciences upgraded to Outperform from Sector Perform at RBC CapitalWave Life Sciences upgraded to Outperform from Sector Perform at RBC Capital

Roger Song

Jefferies

$26

Buy

71.62%

Upside

Reiterated

12/08/25

Wave Life Sciences obesity data met Jefferies' base caseWave Life Sciences obesity data met Jefferies' base case

Catherine Novack

JonesTrading

$20

Buy

32.01%

Upside

Reiterated

09/03/25

Promising Potential in Wave Life Sciences' RNA Editing Technology Justifies Buy Rating Despite Modest Dose Response

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Andrew Fein

H.C. Wainwright

$30

Buy

98.02%

Upside

Reiterated

01/07/26

William Maughan

Clear Street

$22→$47

Buy

210.23%

Upside

Reiterated

01/06/26

Wave Life Sciences (WVE) Gets a Buy from Clear Street

Yun Zhong

Wedbush

$33

Buy

117.82%

Upside

Reiterated

01/06/26

Wave Life Sciences: Validated INHBE Mechanism, Promising WVE-007 Clinical Path, and GLP-1 Combination Upside Support Buy Rating

Benjamin Burnett

Wells Fargo

$29

Buy

91.42%

Upside

Reiterated

12/17/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: BioCryst (NASDAQ: BCRX), Wave Life Sciences (NASDAQ: WVE) and Alkermes (NASDAQ: ALKS)

Cheng Li

Oppenheimer

$24→$32

Buy

111.22%

Upside

Reiterated

12/16/25

Wave Life Sciences price target raised to $32 from $24 at OppenheimerWave Life Sciences price target raised to $32 from $24 at Oppenheimer

Joon Lee

Truist Financial

$36→$50

Buy

230.03%

Upside

Reiterated

12/15/25

Wave Life Sciences (WVE) Receives a Rating Update from a Top Analyst

Madison Elsaadi

B. Riley Securities

$19→$37

Buy

144.22%

Upside

Reiterated

12/11/25

Wave Life Sciences (WVE) Receives a Buy from B. Riley Securities

Steven Seedhouse

Cantor Fitzgerald

$12→$34

Buy

124.42%

Upside

Reiterated

12/09/25

Wave Life Sciences price target raised to $34 from $12 at Cantor FitzgeraldWave Life Sciences price target raised to $34 from $12 at Cantor Fitzgerald

Samantha Semenkow

Citi

$16→$30

Buy

98.02%

Upside

Reiterated

12/09/25

Wave Life Sciences price target raised to $30 from $16 at CitiWave Life Sciences price target raised to $30 from $16 at Citi

Joseph Schwartz

Leerink Partners

$240→$26

Buy

71.62%

Upside

Reiterated

12/08/25

Promising Potential of Wave Life Sciences' WVE-007: A Competitive Candidate in the Weight Loss Market

Whitney Ijem

Canaccord Genuity

$19→$40

Buy

164.03%

Upside

Reiterated

12/08/25

Wave Life Sciences price target raised to $40 from $19 at CanaccordWave Life Sciences price target raised to $40 from $19 at Canaccord

Martin Auster

Raymond James

$21

Buy

38.61%

Upside

Reiterated

12/08/25

Wave Life Sciences' WVE-007: Promising Data and Safety Profile Elevate Buy Rating and Price Target

Luca Issi

RBC Capital

$9→$27

Buy

78.22%

Upside

Upgraded

12/08/25

Wave Life Sciences upgraded to Outperform from Sector Perform at RBC CapitalWave Life Sciences upgraded to Outperform from Sector Perform at RBC Capital

Roger Song

Jefferies

$26

Buy

71.62%

Upside

Reiterated

12/08/25

Wave Life Sciences obesity data met Jefferies' base caseWave Life Sciences obesity data met Jefferies' base case

Catherine Novack

JonesTrading

$20

Buy

32.01%

Upside

Reiterated

09/03/25

Promising Potential in Wave Life Sciences' RNA Editing Technology Justifies Buy Rating Despite Modest Dose Response

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Wave Life Sciences

1 Month

xxx

Success Rate

8/17 ratings generated profit

Average Return

+11.95%

reiterated a xxx

rating yesterday

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 47.06% of your transactions generating a profit, with an average return of +11.95% per trade.

3 Months

xxx

Success Rate

9/19 ratings generated profit

Average Return

+16.10%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 47.37% of your transactions generating a profit, with an average return of +16.10% per trade.

1 Year

Joseph SchwartzLeerink Partners

Success Rate

16/19 ratings generated profit

Average Return

+52.32%

reiterated a buy rating last month

Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 84.21% of your transactions generating a profit, with an average return of +52.32% per trade.

2 Years

xxx

Success Rate

15/17 ratings generated profit

Average Return

+90.53%

reiterated a xxx

rating yesterday

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 88.24% of your transactions generating a profit, with an average return of +90.53% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

WVE Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, WVE has received 27 Buy Ratings, 9 Hold Ratings, and 0 Sell Ratings. WVE average Analyst price target in the past 3 months is 33.00.

Each month's total comprises the sum of three months' worth of ratings.

WVE Financial Forecast

WVE Earnings Forecast

Next quarter’s earnings estimate for WVE is -$0.27 with a range of -$0.35 to -$0.11. The previous quarter’s EPS was -$0.32. WVE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year WVE has Performed in-line its overall industry.

WVE Sales Forecast

Next quarter’s sales forecast for WVE is $17.17M with a range of $7.61M to $47.00M. The previous quarter’s sales results were $7.61M. WVE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year WVE has Performed in-line its overall industry.

WVE Stock Forecast FAQ

What is WVE’s average 12-month price target, according to analysts?

Based on analyst ratings, Wave Life Sciences’s 12-month average price target is 33.00.

What is WVE’s upside potential, based on the analysts’ average price target?

Wave Life Sciences has 117.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is WVE a Buy, Sell or Hold?

Wave Life Sciences has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.

What is Wave Life Sciences’s price target?

The average price target for Wave Life Sciences is 33.00. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $50.00 ,the lowest forecast is $21.00. The average price target represents 117.82% Increase from the current price of $15.15.

What do analysts say about Wave Life Sciences?

Wave Life Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of WVE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Wave Life Sciences (WVE) Stock Forecast & Price Target

WVE Analyst Ratings

WVE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Wave Life Sciences

WVE Analyst Recommendation Trends

WVE Financial Forecast

WVE Earnings Forecast

WVE Sales Forecast

WVE Stock Forecast FAQ

Detailed List of Analyst Forecasts